NS Phrama's Viltepso (viltolarsen) Receives the US FDA's Approval for Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping Therapy
Shots:
- The approval is based on P-II two period study; Study 1 includes patients aged 4-10yrs. conducted in North America and Study 2 includes boys aged 5-18yrs. conducted in Japan. The continued approval of VILTEPSO may contingent on confirmation of clinical benefit in P-III confirmatory trial
- Results: patients receiving the dose of (80 mg/kg/wk)- 100% patients showed increase in dystrophin levels; 88% patients showed dystrophin levels of 3% or greater than normal; after 20-24wks. of treatment- increment in dystrophin expression (6% vs 0.6%)
- Viltepso has received PR designation- RPD- FT & ODD- prior to its FDA’s approval. In Mar’2020- it has received MHLW’s approval- prior to which it received SAKIGAKE- ODD and designation of conditional early approval system
Ref: Pmlive | Image: Pmlive
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com